Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population

The Cytochrome P450 is the major enzyme involved in drug metabolism. CYP enzymes are responsible for the metabolism of most clinically used drugs. Individual variability in CYP activity is one important factor that contributes to drug therapy failure. We have developed a new straightforward TaqMan P...

Full description

Saved in:
Bibliographic Details
Published in:International journal of medical sciences 2015, Vol.12 (1), p.78-82
Main Authors: Ota, Tomoko, Kamada, Yuka, Hayashida, Mariko, Iwao-Koizumi, Kyoko, Murata, Shigenori, Kinoshita, Kenji
Format: Article
Language:English
Subjects:
Asian Continental Ancestry Group - genetics
Cytochrome P-450 CYP1A2 - genetics
Cytochrome P-450 CYP2C19 - genetics
Cytochrome P-450 CYP2C9 - genetics
Cytochrome P-450 CYP2D6 - genetics
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 Enzyme System - genetics
Gene Frequency
Genetics, Population
Humans
Inactivation, Metabolic - genetics
Polymorphism, Genetic
Research Paper
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Cytochrome P450 is the major enzyme involved in drug metabolism. CYP enzymes are responsible for the metabolism of most clinically used drugs. Individual variability in CYP activity is one important factor that contributes to drug therapy failure. We have developed a new straightforward TaqMan PCR genotyping assay to investigate the prevalence of the most common allelic variants of polymorphic CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Moreover, we focused on the combination of each genotype for clinical treatment. The genotype analysis identified a total of 139 out of 483 genotype combinations of five genes in the 1,003 Japanese subjects. According to our results, most of subjects seemed to require dose modification during clinical treatment. In the near future, modifications should be considered based on the individual patient genotype of each treatment.
ISSN:1449-1907
1449-1907
DOI:10.7150/ijms.10263